World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
134
Citations
59674
World Ranking
2165
National Ranking
1224

William D. Figg publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where William D. Figg sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,021 publications — 95th percentile

95% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

William D. Figg D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where William D. Figg sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 134 D-Index — 90th percentile

90% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

William D. Figg is affiliated with the National Institutes of Health in the United States. Their research spans multiple fields within medicine and biochemistry, genetics, and molecular biology. The scientist has contributed extensively to oncology, pulmonary and respiratory medicine, molecular biology, genetics, and radiology, nuclear medicine, and imaging.

Their recent publications cover various aspects of cancer and diagnostics, including:

  • Selumetinib in Children with Inoperable Plexiform Neurofibromas, 2020, New England Journal of Medicine
  • Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress, 2021, Cancer Cell
  • COVID-19 Clinical Diagnostics and Testing Technology, 2020, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  • Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors, 2020, Journal of Clinical Oncology
  • Resistance to second-generation androgen receptor antagonists in prostate cancer, 2021, Nature Reviews Urology

William D. Figg frequently collaborates with a core group of coauthors, including:

  • Cody J. Peer (89 publications)
  • Seth M. Steinberg (52 publications)
  • Cindy H. Chau (34 publications)
  • James L. Gulley (31 publications)
  • Fatima Karzai (29 publications)

Their research appears regularly in several prominent scientific journals, with frequent contributions to:

  • Journal of Clinical Oncology (37 publications)
  • Blood (18 publications)
  • The Journal of Clinical Pharmacology (16 publications)
  • Cancer Research (8 publications)
  • The Oncologist (7 publications)

William D. Figg's main fields of study include Medicine, with 430 publications, and Biochemistry, Genetics, and Molecular Biology, accounting for 118 publications. Their subfields of focus reflect a concentration on:

  • Oncology (113 publications)
  • Pulmonary and Respiratory Medicine (82 publications)
  • Molecular Biology (75 publications)
  • Genetics (48 publications)
  • Radiology, Nuclear Medicine, and Imaging (35 publications)

The scientist's work covers a range of main topics, guiding cancer research and treatment strategies, notably in:

  • Prostate Cancer Treatment and Research (90 publications)
  • Cancer Immunotherapy and Biomarkers (56 publications)
  • Chronic Lymphocytic Leukemia Research (44 publications)
  • Lymphoma Diagnosis and Treatment (36 publications)
  • Radiopharmaceutical Chemistry and Applications (32 publications)
  • Lung Cancer Research Studies (28 publications)
  • Multiple Myeloma Research and Treatments (28 publications)

Best Publications

  • Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

    Howard I. Scher;Susan Halabi;Ian Tannock;Michael Morris

  • Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

    Glenn J. Bubley;Michael Carducci;William Dahut;Nancy Dawson

  • Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer

    Kevin C. Conlon;Enrico Lugli;Hugh C. Welles;Hugh C. Welles;Steven A. Rosenberg

  • Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

    Richard L. Piekarz;Robin Frye;Maria Turner;John J. Wright

  • Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.

    Austin G. Duffy;Susanna V. Ulahannan;Oxana Makorova-Rusher;Osama Rahma

  • Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

    Victor Sandor;Susan Bakke;Robert W Robey;Min H Kang

  • Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents

    Alex Sparreboom;Michael C. Cox;Milin R. Acharya;William D. Figg

  • Antibody–drug conjugates for cancer

    Cindy H Chau;Patricia S Steeg;William D Figg

  • Angiogenesis inhibitors: current strategies and future prospects.

    Kristina M. Cook;William D. Figg

  • Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas

    Howard A. Fine;William D. Figg;Kurt Jaeckle;Patrick Y. Wen

  • Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)

    Alex Sparreboom;Charity D. Scripture;Vuong Trieu;Paul J. Williams

  • Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer

    Elisabetta Mueller;Matthew Smith;Pasha Sarraf;Todd Kroll

  • Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

    Richard L. Piekarz;Robin Frye;H. Miles Prince;Mark H. Kirschbaum

  • Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

    A M Senderowicz;D Headlee;S F Stinson;R M Lush

  • Selumetinib in Children with Inoperable Plexiform Neurofibromas

    Andrea M. Gross;Pamela L. Wolters;Eva Dombi;Andrea Baldwin

  • Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma

    Qin C. Ryan;Donna Headlee;Milin Acharya;Alex Sparreboom

  • Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer

    Alain Thibault;Dvorit Samid;Dvorit Samid;Anne C. Tompkins;William D. Figg

  • Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer

    William L. Dahut;James L. Gulley;Philip M. Arlen;Yinong Liu

  • Drug interactions in cancer therapy.

    Charity D. Scripture;William D. Figg

  • A Randomized Phase II Trial of Thalidomide, an Angiogenesis Inhibitor, in Patients with Androgen-independent Prostate Cancer

    William D. Figg;William Dahut;Paul Duray;Michael Hamilton

Frequent Co-Authors

Seth M. Steinberg
Seth M. Steinberg National Institutes of Health
James L. Gulley
James L. Gulley National Institutes of Health
Alex Sparreboom
Alex Sparreboom The Ohio State University
Eddie Reed
Eddie Reed National Institutes of Health
Philip M. Arlen
Philip M. Arlen National Institutes of Health
David Venzon
David Venzon National Institutes of Health
Jane B. Trepel
Jane B. Trepel National Institutes of Health
Elise C. Kohn
Elise C. Kohn National Institutes of Health
Susan E. Bates
Susan E. Bates Columbia University
Peter L. Choyke
Peter L. Choyke National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online healthcare degrees can be a flexible and affordable way to advance your medical career in the USA. Many aspiring nurses and healthcare professionals are looking for the cheapest dnp programs online to save on tuition while still gaining the credentials needed for leadership roles.

One key consideration is understanding the average cost of rn to bsn programs. Costs can vary greatly, so researching affordable and accredited options can make a significant difference in your investment and future earnings.

If you’re transitioning into nursing without a prior nursing background, direct msn programs online offer accelerated pathways. These programs are designed for non-nursing graduates and can help you fast-track into advanced nursing roles.

Finally, prospective students often look for easy nursing schools to get into to maximize their chances of acceptance. These schools may offer flexible admission requirements and can be ideal for students starting out or looking for a career change in healthcare.

Best Scientists Citing William D. Figg

Trending Scientists

Recently Published Articles